Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
| PreciseDx Presents New Research on Their AI-Enabled Digital Test at 14th Annual European Breast Conference | ||
| By: PR Newswire Association LLC. - 22 Mar 2024 | Back to overview list |
|
|
The presentation, "Clinical validation of an artificial-intelligent (AI) enabled digital test using the patient's diagnostic breast biopsy to predict invasive breast cancer recurrence within 6-years," will be held 3/22/24 NEW YORK, March 22, 2024 /PRNewswire-PRWeb/ -- PreciseDx®, a leading innovator in oncology diagnostics leveraging Artificial Intelligence (AI) for revolutionary, morphology-driven disease analysis, today announced their attendance and participation at the 14th Annual European Breast Conference in Milan, Italy. PreciseDx Co-Founder and Chief Medical Officer, Michael J. Donovan, PhD, MD is presenting the findings from the PreciseBreast™ biopsy clinical validation study through a poster presentation. "This study marks a notable milestone in oncology prognosis, reflecting the continued advancement of breast cancer research and treatment. It also underscores PreciseDx's commitment to enhancing patient outcomes through innovative technologies," said Dr. Donovan. As part of the overall validation process, PreciseDx has conducted a series of first-in-class analytical studies, including precision, repeatability, and reproducibility, to assess methodological variability for both surgical excision and biopsy specimens. Collectively, these activities support the robustness and accuracy of the platform to predict risk of early-stage invasive breast cancer recurrence within 6 years. "This study marks a notable milestone in oncology prognosis, reflecting the continued advancement of breast cancer research and treatment. It also underscores PreciseDx's commitment to enhancing patient outcomes through innovative technologies," said Dr. Donovan. "We look forward to sharing the outcomes of our breast biopsy clinical validation study with a diverse group of international, multidisciplinary conference attendees at the European Breast Cancer Conference." The full poster presentation details can be found here:
The European Breast Cancer Conference, the first conference of its kind, started in 1998. Its purpose was to provide a platform for breast cancer specialists and patients to discuss the multidisciplinary approach to breast cancer care and provide specialists with the latest updates in treatment. About PreciseDx PreciseDx® is innovating oncology diagnostics, leveraging Artificial Intelligence (AI) for revolutionary, morphology-driven disease analysis. Combining AI with our patented Morphology Feature Array® (MFA), PreciseDx provides access to unmatched disease insights and accurate, actionable intelligence for more comprehensive decision-making throughout the cancer care continuum. To learn more about PreciseDx, visit https://precisedx.ai/ About PreciseBreast™ PreciseBreast™ is an early-stage invasive breast cancer risk assessment, independent of Her2, hormone receptor, and nodal status. The AI-powered test collects millions of data points, analyzes, correlates, and quantifies those that are critical features of predicting breast cancer recurrence and delivers a Risk of Recurrence Score. The Test meets the rigorous Clinical Laboratory Improvement Amendments (CLIA) standards and. It has passed the Clinical Laboratory Evaluation Program (CLEP) Assay Validation Review by the New York State Department of Health (NYSDOH). For more information, please contact precisebreast@precisedx.ai. About EBCC Europe's most exciting international cancer conference is the only one to involve all the major players in breast cancer, encouraging interaction between scientists, clinicians, and patient representatives in a partnership of equals to talk not just about the very latest scientific advances, but also the ethical, social, political, and practical issues associated with caring for patients with breast cancer. EBCC-14 is expected to attract around 2000 delegates from around 80 countries worldwide. The conference covers the entire spectrum of breast cancer and highlights what is new across fields as diverse as:
Media Contact Hannah Davis, 0to5 for PreciseDx, 1 860.707.9461, hannah@0to5.com
SOURCE 0to5 for PreciseDx 
|
||
|
|
||
 | Back to overview list | |
View original content: